# RougeTx

> Preclinical biotech developing disease-modifying therapies for vascular disorders by targeting pericyte dysfunction.

## Why it is interesting

RougeTx launched with a large Series A around a specific vascular-biology thesis and a platform intended to extend beyond hereditary hemorrhagic telangiectasia.

## Profile

- **Latest funding:** Series A — $58M (October 6, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $58M
- **Stage:** series-a
- **Status:** private
- **Industries:** N/A
- **Coverage:** stub
- **Last updated:** 2026-10-07
- **Latest funding investors:** BioGeneration Ventures, Angelini Ventures, Kurma Partners, Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest, Kerna Ventures

## Funding history

- Series A · $58M · October 6, 2026
  Source: https://www.globenewswire.com/news-release/2026/10/06/3375146/0/en/rougetx-launches-with-58-million-series-a-financing-to-advance-first-in-class-treatment-for-hereditary-hemorrhagic-telangiectasia.html

## Related articles

- https://venturecapitaltracker.com/2026-rougetx-58m-series-a-hht

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 7, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/rougetx